Organovo Holdings Accounts Receivables 2011-2026 | ONVO

Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.

Examples of accounts receivable

Customers have not paid invoices for delivered products
An advance has been paid to a supplier, but goods have not yet been received
Employees have not reported on accountable amounts
The government must refund tax overpayments
Outstanding loans issued

Importance of accounts receivable in company analysis

Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment.
Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages.
Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)

Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)

If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.

Annual Accounts Receivables Organovo Holdings

2025	2024	2023	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
30 K	33 K	152 K	-	111 K	503 K	883 K	647 K	259 K	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
883 K	30 K	327 K

Quarterly Accounts Receivables Organovo Holdings

2025-Q4	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
33 K	32 K	32 K	30 K	26 K	29 K	48 K	33 K	33 K	55 K	149 K	152 K	76 K	-	-	-	-	-	-	-	-	19 K	84 K	111 K	165 K	619 K	538 K	503 K	547 K	475 K	628 K	883 K	1.17 M	1.03 M	772 K	647 K	1.03 M	606 K	103 K	259 K	165 K	180 K	132 K	-	-	30 K	60 K	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
1.17 M	19 K	311 K

Accounts Receivables of other stocks in the Diagnostics research industry

Issuer	Accounts Receivables	Price	% 24h	Market Cap	Country
Fulgent Genetics FLGT	69 M	$ 15.96	5.63 %	$ 483 M	USA
Burning Rock Biotech Limited BNR	88.2 M	$ 16.76	1.09 %	$ 177 M	China
Castle Biosciences CSTL	43.4 M	$ 19.83	3.07 %	$ 575 M	USA
Agilent Technologies A	1.17 B	$ 115.62	-2.55 %	$ 35.1 B	USA
Akumin AKU	114 M	-	-17.87 %	$ 25.9 M	Canada
Aspira Women's Health AWH	1.21 M	-	-6.19 %	$ 10.5 M	USA
Accelerate Diagnostics AXDX	2.42 M	-	-61.36 %	$ 2.46 M	USA
Biocept BIOC	2.15 M	-	-13.05 %	$ 7.29 M	USA
CareDx, Inc CDNA	42.6 M	$ 21.82	1.77 %	$ 1.16 B	USA
Chembio Diagnostics CEMI	6.54 M	-	0.22 %	$ 16.8 M	USA
Lantheus Holdings LNTH	359 M	$ 93.06	2.26 %	$ 6.28 B	USA
HTG Molecular Diagnostics HTGM	1.42 M	-	-20.0 %	$ 1.06 M	USA
Medpace Holdings MEDP	402 M	$ 424.0	-1.1 %	$ 12.2 B	USA
Co-Diagnostics CODX	190 K	$ 2.53	31.09 %	$ 3.37 M	USA
Myriad Genetics MYGN	115 M	$ 4.29	4.89 %	$ 397 M	USA
NeoGenomics NEO	159 M	$ 8.96	-1.21 %	$ 1.15 B	USA
National Research Corporation NRC	11.1 M	$ 18.75	0.11 %	$ 420 M	USA
Global Cord Blood Corporation CO	416 M	-	-	$ 399 M	China
Natera NTRA	244 M	$ 194.24	-11.64 %	$ 19.1 B	USA
DermTech DMTK	2.58 M	-	-11.32 %	$ 2.94 M	USA
Charles River Laboratories International CRL	709 M	$ 177.62	-2.23 %	$ 8.8 B	USA
Enzo Biochem ENZ	3.99 M	-	-8.98 %	$ 14.8 K	USA
Exact Sciences Corporation EXAS	299 M	-	-	$ 19.8 B	USA
Personalis PSNL	16.2 M	$ 5.98	-0.17 %	$ 534 M	USA
Guardant Health GH	138 M	$ 95.7	3.73 %	$ 12 B	USA
Senseonics Holdings SENS	127 K	$ 5.03	-6.16 %	$ 210 M	USA
Soleno Therapeutics SLNO	28.2 M	$ 52.95	-	$ 2.69 B	USA
Heska Corporation HSKA	29.5 M	-	-	$ 1.31 B	USA
ICON Public Limited Company ICLR	1.34 B	$ 124.49	-0.41 %	$ 10.3 B	Irlanda
Illumina ILMN	735 M	$ 141.88	2.29 %	$ 22.6 B	USA
Interpace Biosciences IDXG	5.65 M	$ 1.95	-2.5 %	$ 8.63 M	USA
QIAGEN N.V. QGEN	381 M	-	-	$ 10.6 B	Niderland
Twist Bioscience Corporation TWST	57 M	$ 56.85	-2.89 %	$ 3.4 B	USA
Biomerica BMRA	731 K	$ 2.15	-2.05 %	$ 4.94 M	USA
Thermo Fisher Scientific TMO	8.9 B	$ 465.0	-1.99 %	$ 175 B	USA
Laboratory Corporation of America Holdings LH	2.1 B	$ 254.12	-1.52 %	$ 21.1 B	USA
Motus GI Holdings MOTS	76 K	-	-34.28 %	$ 263 K	Israel
Waters Corporation WAT	829 M	$ 355.13	1.32 %	$ 21.1 B	USA
Neogen Corporation NEOG	153 M	$ 9.05	-2.16 %	$ 1.96 B	USA
Quest Diagnostics Incorporated DGX	1.41 B	$ 187.39	-1.82 %	$ 20.8 B	USA